Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 3NIH 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Endocrine 2NET 1

Conditions

Neoplasms 46Multiple Myeloma 45Lymphoma 43Neoplasm Metastasis 40Breast Neoplasms 38Lung Neoplasms 37Prostatic Neoplasms 32Carcinoma, Non-Small-Cell Lung 30Leukemia, Myeloid, Acute 28Colorectal Neoplasms 28Melanoma 27Ovarian Neoplasms 25Hematologic Neoplasms 22Urinary Bladder Neoplasms 21Pancreatic Neoplasms 21Lymphoma, Non-Hodgkin 20Glioma 20Carcinoma, Renal Cell 19Sarcoma 18Triple Negative Breast Neoplasms 15Stomach Neoplasms 15Myelodysplastic Syndromes 15Burkitt Lymphoma 15Neuroblastoma 14Lymphoma, Large B-Cell, Diffuse 13Fallopian Tube Neoplasms 13Ependymoma 13Carcinoma 13Brain Neoplasms 13Thyroid Neoplasms 12

Interventions

olaparib 1lutetium Lu 177 dotatate 1fluorodopa F 18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Carcinoid Tumor × 30 days × Clear all
NCT04086485 2026-05-22

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
56 enrolled
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

NCT00646022 2026-05-12

Natural History of Familial Carcinoid Tumor

National Institutes of Health Clinical Center (CC)

Recruiting
1,600 enrolled
Endocrine

Carcinoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡